Video: Dr. Emili Montserrat Keynote – CCOLD 2010 Hematology Part 1 Part 2 Watch more videos Show All /leukemia /Lung /lymphoma /Pancreatic Dr. Neesha Dhani discusses dose modification of nanoliposomal irinotecan plus 5-FU/LV in NAPOLI-1ASCO GI 2018Dr. Yoo-Joung Ko discusses subgroup analysis by measurable metastatic lesion number and selected lesion locations at baseline in NAPOLI-1ASCO GI 2018Dr. Neesha Dhani discusses nanoliposomal irinotecan and 5-FU/LV for the treatment of advanced PDACASCO GI 2018Dr. Yoo-Joung Ko shares his thoughts on the nomogram for predicting overall survival in patients treated with nanoliposomal irinotecan ± 5-FU/LV in mPDAC previously treated with gemcitabine-based therapy in NAPOLI-1ASCO GI 2018Dr. Doug Stewart on Maintenance Rituximab Following Bendamustine-Rituximab for Follicular Lymphoma in the MAINTAIN and BRIGHT trialsASH 2017Dr. Yoo-Joung Ko discusses results from the safety run in of a randomized phase II study of gemcitabine (gem) and nab-paclitaxel (nab-P) versus gem, nab-P, durvalumab, and tremelimumab as first-line therapy in mPDACASCO GI 2018An Interview with GIBB Trial Investigator Dr. Jeff Sharman on Quality of Life and Symptoms in First-Line Obinutuzumab and Bendamustine for CLLASH 2017Dr. Mathias Rummel shares his perspectives and takeaways from the MAINTAIN studyASH 2017Dr. Mathias Rummel discusses the design and results of the MAINTAIN studyASH 2017Dr. Carolyn Owen discusses the results of the GALLIUM trialASH 2017Dr. Normand Blais discusses the findings of the FLAURA trial presentedESMO 2017Dr. Mark Vincent discusses the findings of the FLAURA trial presentedESMO 2017Dr. Barb Melosky analyzes the findings of the FLAURA trial presentedESMO 2017Dr. Christine Brezden-Masley on baseline NLRs in predicting clinical outcomes in mPDAC patientsESMO 2017Dr. Alice Wei on baseline NLRs in predicting clinical outcomes in mPDAC patientsESMO 2017Dr. Christine Brezden-Masley’s perspective on the NIFE trialESMO 2017Dr. Alice Wei’s perspective on the NIFE trialESMO 2017Dr. Mathias Rummel discusses outcomes and key takeaways from the StiL NHL1 trialASCO 2017Dr. Mathias Rummel discusses the objectives and the updated findings of the StiL NHL1 trialACO 2017Dr. Winson Cheung compares different schedules of nab-paclitaxel with gemcitabine in mPDAC treatmentASCO 2017Dr. Sharlene Gill discusses adding napabucasin to gemcitabine/nab-paclitaxel therapy in mPDACASCO 2017Dr. Winson Cheung discusses “Subgroup analysis by prior lines of metastatic therapy in NAPOLI-1″ASCO 2017Dr. Sharlene Gill discusses subgroup analyses by prior lines of metastatic therapy in NAPOLI-1ASCO 2017Dr. Laurie Sehn on first-line treatment of iNHL and MCL and BRIGHT and StiL NHL1 trial designASCO 2017Dr. Laurie Sehn discusses the results of the BRIGHT and StiL NHL1 trials presentedASCO 2017Dr. Laurie Sehn discusses key takeaways from the BRIGHT and StiL NHL1 trials presentedASCO 2017An Interview with Dr. Bruce Cheson on findings from the GADOLIN studyASH 2016Dr. Sandy Sehdev shares his perspectives on nal-IRI and NAPOLI-1ESMO 2016Dr. Mark Vincent shares his perspectives on nal-IRI and NAPOLI-1ESMO 2016Dr. Wojtek Morzycki shares his perspectives on afatinib and LUX-Lung 7ESMO 2016Dr. Robert El-Maraghi shares his perspectives on afatinib and LUX-Lung 7ESMO 2016Dr. Sandy Sehdev shares his perspectives on Afatinib and LUX-Lung 7ESMO 2016Dr. Normand Blais shares his perspectives on Afatinib and LUX-Lung 7ESMO 2016Canadian KOLs discuss the impact of the NAPOLI-1 results on their clinical practiceESMO 2016Canadian KOLs share their take-home messages from LUX-Lung 7ESMO 2016Impact of LUX-Lung 7 results on Canadian practiceESMO 2016Perspectives from Dr. Simon RaphaelASCO 2016Dr. Graeme Fraser on a Two-year Follow-up of the HELIOS StudyASCO 2016An Interview with Dr. Vera Hirsh on the Effect of Afatinib Dose Adjustments on Efficacy, AEs, and Quality of Life in the LUX-Lung 7 TrialASCO 2016Importance of Attending CLCCO: Perspectives from Canada’s Lung ExpertsCLCCO 2016Dr. Robert El-Maraghi shared his perspective on LUX-Lung 7 ResultsCLCCO 2016Dr. Mark Vincent shared his perspective on LUX-Lung 7 ResultsCLCCO 2016An Interview with Dr. Simon Rule on the MCL3001 RAY TrialASH 2015Canadian oncologists give their insights on PD-1 immune checkpoint inhibitorsESMO ASIA 2015/CLCCO 2016Dr. Sunil Yadav shared his perspective on LUX-Lung 7ESMO 2015Dr. Tony Mok shared his perspective on LUX-Lung 7ESMO 2015Dr. Sandy Sehdev shared his perspective on LUX-Lung 7ESMO 2015Dr. Barbara Melosky shared her perspective on LUX-Lung 7ESMO 2015Dr. Wojtek Morzycki on the LUX-Lung 8, LUX-Lung 7, and IMPRESS trialsESMO 2015Dr. Robert El-Maraghi on the LUX-Lung 8, LUX-Lung 7, and IMPRESS trialsESMO 2015A Brief Update and Perspective on Lung Cancer with Dr. Sunil VermaESMO 2015Dr. Mathias Rummel InterviewCCOLD 2012Dr. John Kuruvilla PresentationCCOLD 2012Dr. Michael Hallek KeynoteCCOLD 2012Dr. Gilles Salles KeynoteCCOLD 2011Dr. Michael Hallek InterviewCCOLD 2012Dr. M. DreylingCCOLD 2011Dr. Clemens-Martin Wendtner KeynoteCCOLD 2010Dr. Joseph M. ConnorsCCOLD 2011Dr. Emili Montserrat KeynoteCCOLD 2010LOAD MORE LOADING...NO MORE WORKS Videos Papers Slides Best Practice Cases
